Adult onset Still's disease after first cycle of pemetrexed and gemcitabine for non-small cell lung cancer
Joaquim Bosch-Barrera (a) , Alberto Montero (b), José María López-Picazo (a), Jesús García-Foncillas (a), Marta Ferrer (c), José Ramón Yuste (b), Ignacio Gil-Bazo (a)
(a) Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain
(b) Division of Infectious Diseases, Clínica Universidad de Navarra, Pamplona, Spain
(c) Department of Allergy and Clinical Immunology, Clínica Universidad de Navarra, Pamplona, Spain
Pemetrexed is a multitargeted antifolate approved for the second-line treatment of locally advanced or metastatic non-small cell lung cancer. The combination of pemetrexed with gemcitabine has been studied in several clinical trials showing a promising antitumor activity with a mild toxicity profile.
We present the case of a patient who experienced fever, arthralgia, skin rash and high serum ferritin levels after first cycle of this chemotherapy combination, compatible with an adult onset Still's disease. This adverse event has not been previously reported.
CITA DEL ARTÍCULO Lung Cancer. 2009 Apr;64(1):124-6